We and others in previous publications have extensively investigated the abnormalities in lipoprotein metabolism in individuals with more pronounced type 2 diabetes and have shown increased ApoB-48 production by the intestine and demonstrated that GLP-1 receptor agonists reduce the intestinal ApoB-48 overproduction [44, 49, 69]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.